Editorial team
ioQuanta Research Desk
-
Evidence date ·Treating uterine leiomyosarcoma raises two different questions
Review or Meta-AnalysisA 2021 review explains why chemotherapy after surgery remains unsettled, outlines options for advanced disease, and reports no benefit from two tested add-ons.
-
Evidence date ·What does it take to make a continuous fiber from nanocellulose?
Review or Meta-AnalysisA 2021 review describes spinning nanocellulose on its own or with polymers, a distinction that matters when judging claims about replacing petroleum-based materials.
-
Evidence date ·Why starch type and spinning method matter for making fibers
Review or Meta-AnalysisA 2021 review describes fibers thinner than a micrometer made from corn and potato starch; limited strength and moisture sensitivity still challenge textile use.
-
Evidence date ·How a skin biopsy changed care during lung cancer treatment
Review or Meta-AnalysisAn older woman developed itching before biopsy-confirmed bullous pemphigoid during pembrolizumab treatment; the authors found 19 earlier cases, three in lung cancer.
-
Evidence date ·How nerve and muscle weakness unfolded in two patients receiving targeted cancer drugs
Review or Meta-AnalysisTwo cases describe facial weakness during prolonged melanoma treatment and muscle weakness within days of starting imatinib. The second patient needed ventilation.
-
Evidence date ·Why immune treatments can activate defenses or teach restraint
Review or Meta-AnalysisCheckpoint antibodies can release a brake tumors use against T cells, while repeated allergen doses aim to build tolerance. The review brings together evidence at different stages.
-
Evidence date ·Why researchers considered beta blockers alongside melanoma treatment
Review or Meta-AnalysisA 2021 review describes reports of reduced melanoma recurrence and a link between beta blockers and longer survival when melanoma has spread.
-
Evidence date ·When B-ALL returns, what can doctors target on leukemia cells?
Review or Meta-AnalysisWhen B-cell acute lymphoblastic leukemia returns, immune therapies could target CD19, CD20 or CD22 on the cancer cells.
-
Evidence date ·What brain scans showed with two immune drugs or one plus radiation
Review or Meta-AnalysisAcross separate studies, brain tumors shrank most often with two immune drugs, while one drug plus radiation had the highest rate when stable tumors also counted.
-
Evidence date ·What can two cases tell us about treating brain metastases with radiation and immune therapy?
Review or Meta-AnalysisTwo patients with lung cancer received both brain radiation and immune checkpoint treatment, a combination for which safety data remain limited.